We have shown here that treatment with the same IC that are increased in lesions and blood of KS patients or in subjects at risk of disease development enhances the severity and delays the regression of KS-like lesions arising in BKV/Tat transgenic mice. This evidence concerns the gene TAT and Kaposi's sarcoma.